Amir A Jazaeri

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. pmc Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924
    Amir A Jazaeri
    Corresponding Author Amir A Jazaeri, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Box 800712, Charlottesville, VA 22908
    Mol Cancer Ther 12:1958-67. 2013
  2. pmc Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma
    Amir A Jazaeri
    W Norman Thornton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Neoplasia 13:899-911. 2011
  3. doi Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer
    Amir A Jazaeri
    W Norman Thornton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Gynecol Oncol 118:189-95. 2010
  4. doi Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease
    Amir A Jazaeri
    W Norman Thornton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Box 800712, Charlottesville, VA 22908, USA
    Mol Oncol 3:151-6. 2009
  5. doi Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report
    Daniel P Greene
    University of Virginia School of Medicine, Charlottesville, VA, USA
    Cancer Chemother Pharmacol 66:265-7. 2010
  6. doi Utilization of a uniform grading system for interpreting serous ovarian cancer
    Jason A Lachance
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Am J Obstet Gynecol 199:189.e1-6. 2008
  7. ncbi Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer
    Megan B Callahan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA
    Am J Obstet Gynecol 197:199.e1-4; discussion 199.e4-5. 2007
  8. ncbi A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma
    Jason A Lachance
    Division of Gynecologic Oncology, University of Virginia Health System, Charlottesville, VA, USA
    Gynecol Oncol 108:77-83. 2008
  9. doi A nomogram for estimating the probability of ovarian cancer
    Jason A Lachance
    Department of Obstetrics Gynecology, Division of Gynecologic Oncology, University of Virginia Health System, USA
    Gynecol Oncol 121:2-7. 2011
  10. doi Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series
    J Stuart Ferriss
    Department of Obstetrics and Gynecology, University of Virginia Health System, PO Box 800712, Charlottesville, VA 22908, USA
    Int J Gynecol Cancer 20:120-5. 2010

Collaborators

Detail Information

Publications19

  1. pmc Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924
    Amir A Jazaeri
    Corresponding Author Amir A Jazaeri, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Box 800712, Charlottesville, VA 22908
    Mol Cancer Ther 12:1958-67. 2013
    ..This investigation identifies inhibition of neddylation as a novel mechanism for overcoming platinum resistance in vitro, and provides a strong rationale for clinical investigations of platinum and MLN4924 combinations in ovarian cancer...
  2. pmc Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma
    Amir A Jazaeri
    W Norman Thornton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Neoplasia 13:899-911. 2011
    ..Thus, our investigation supports the tubal origin of serous carcinoma and provides a dynamic model for studying early molecular alterations in serous carcinogenesis...
  3. doi Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer
    Amir A Jazaeri
    W Norman Thornton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Gynecol Oncol 118:189-95. 2010
    ..Overexpression of EVI1 in ovarian cancer has led to a proposed oncogenic role. Our objective was to evaluate the therapeutic potential of EVI1 and EVI1s (also known as Delta324) in ovarian cancer...
  4. doi Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease
    Amir A Jazaeri
    W Norman Thornton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Box 800712, Charlottesville, VA 22908, USA
    Mol Oncol 3:151-6. 2009
    ..The purpose of this review is to consider the available data on ovarian cancers in the context of other investigations of BRCA-related transcriptional alterations, and highlight areas for future research...
  5. doi Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report
    Daniel P Greene
    University of Virginia School of Medicine, Charlottesville, VA, USA
    Cancer Chemother Pharmacol 66:265-7. 2010
    ..In this brief report, we present case of successful cisplatin administration following two unsuccessful carboplatin desensitization attempts, and without the need for pre-treatment steroids...
  6. doi Utilization of a uniform grading system for interpreting serous ovarian cancer
    Jason A Lachance
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Am J Obstet Gynecol 199:189.e1-6. 2008
    ..The purpose of the study was to implement a uniform system for assigning tumor grade in serous ovarian cancer and evaluate its correlation with response to conventional chemotherapy...
  7. ncbi Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer
    Megan B Callahan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA
    Am J Obstet Gynecol 197:199.e1-4; discussion 199.e4-5. 2007
    ..The purpose of this study was to evaluate the results of substituting cisplatin for carboplatin in women who experienced a carboplatin-associated hypersensitivity reaction while undergoing treatment for gynecologic cancers...
  8. ncbi A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma
    Jason A Lachance
    Division of Gynecologic Oncology, University of Virginia Health System, Charlottesville, VA, USA
    Gynecol Oncol 108:77-83. 2008
    ..Our goal was to evaluate the cost-effectiveness of these alternatives for management of stage I endometrial adenocarcinoma...
  9. doi A nomogram for estimating the probability of ovarian cancer
    Jason A Lachance
    Department of Obstetrics Gynecology, Division of Gynecologic Oncology, University of Virginia Health System, USA
    Gynecol Oncol 121:2-7. 2011
    ..This study presents a new statistical model for combining predictive information and a graphic decision support tool for calculating risk of malignancy...
  10. doi Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series
    J Stuart Ferriss
    Department of Obstetrics and Gynecology, University of Virginia Health System, PO Box 800712, Charlottesville, VA 22908, USA
    Int J Gynecol Cancer 20:120-5. 2010
    ..Our objective was to retrospectively review temozolomide in advanced and recurrent uterine leiomyosarcoma and to determine if tumor O-methylguanine DNA methyltransferase (MGMT) expression correlated with clinical response...
  11. ncbi Cervical adenocarcinoma in situ: the predictive value of conization margin status
    Jennifer L Young
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville 22908 0712, USA
    Am J Obstet Gynecol 197:195.e1-7; discussion 195.e7-8. 2007
    ..We evaluated the impact of conization margin status on outcomes of patients diagnosed with cervical adenocarcinoma in situ...
  12. doi Frailty: an outcome predictor for elderly gynecologic oncology patients
    Madeleine Courtney-Brooks
    Thornton Gynecology Oncology Service, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Gynecol Oncol 126:20-4. 2012
    ..The objective of this pilot study was to determine if frailty predicts surgical complications among elderly women undergoing gynecologic oncology procedures...
  13. doi Appendiceal pathology at the time of oophorectomy for ovarian neoplasms
    Julia Timofeev
    W Norman Thornton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, Virginia, USA
    Obstet Gynecol 116:1348-53. 2010
    ..To investigate the prevalence of appendiceal pathology in women undergoing surgery for a suspected ovarian neoplasm and the predictive value of intraoperative findings to determine the need for appendectomy at the time of surgery...
  14. ncbi Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer
    Elise N Everett
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Virginia Health System, Charlottesville, VA 22908 0712, USA
    Am J Obstet Gynecol 195:568-74; discussion 574-6. 2006
    ..The purpose of this study was to evaluate differences in morbidity, progression-free interval, and survival in women with advanced epithelial ovarian cancer treated with initial chemotherapy versus initial surgery...
  15. pmc CRL4(Cdt2) E3 ubiquitin ligase monoubiquitinates PCNA to promote translesion DNA synthesis
    Kenta Terai
    Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA 22908, USA
    Mol Cell 37:143-9. 2010
    ..We propose that CRL4(Cdt2) regulates PCNA-dependent TLS associated with stresses accompanying DNA replication...
  16. ncbi Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics
    Susan C Modesitt
    University of Virginia Health Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Box 800712, Charlottesville, VA 22932, USA
    Expert Opin Pharmacother 8:2293-305. 2007
    ..The purpose of this paper is to review the existing treatment options, including surgery, traditional chemotherapy as well as upcoming novel and targeted therapies that may one day improve outcomes in this disease...
  17. pmc Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors
    Eusebio S Pires
    Department of Cell Biology at The School of Medicine, University of Virginia, Charlottesville, Virginia, USA
    Oncotarget 6:30194-211. 2015
    ....
  18. doi Cyclooxygenase-2 in cervical neoplasia: a review
    Jennifer L Young
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 22908 0712, USA
    Gynecol Oncol 109:140-5. 2008
    ..This review investigates the role of cyclooxygenase-2 (COX-2) in the development of cervical cancer and potential therapeutic options targeting this pathway...
  19. ncbi Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors
    Laurel W Rice
    Norman Thornton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 22908, USA
    Am J Obstet Gynecol 194:1119-26; discussion 1126-8. 2006
    ..The purpose of this study was to investigate the AKT signaling cascade in endometrial cancers and to assess its therapeutic potential...